Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
https://www.globenewswire.com/news-release/2023/09/07/2739524/0/en/RadView-Software-Announces-WebLOAD-13-0.html
RadView Software Ltd. (OTCMKTS:RDVWF), a global leader in load and performance testing solutions, today announced the release of WebLOAD 13.0, the latest version of its flagship product. The update introduces groundbreaking features such as integration with OpenAI's language model, ChatGPT, and text-based load templates to support the most complex web applications with more flexibility and precision.
WebLOAD 13.0 represents a significant step forward in load testing technology, combining the innovative power of AI and user-friendly JSON-based test planning to redefine the way performance testing is conducted and analyzed.
"WebLOAD 13.0 is a leap towards the future of load testing. We've integrated OpenAI's ChatGPT to create an ‘Explainer’ panel that interprets and explains performance data. It brings a new level of understanding to load testing, which was previously unattainable" said Mr. Firas Matar, RadView CEO.
The introduction of WebLOAD 13.0 extends RadView's commitment to providing advanced load testing solutions that help businesses deliver high-performing web applications to their users. Despite the introduction of these innovative features, WebLOAD continues to offer the most flexible deployment options and the highest level of enterprise support, staying true to RadView's founding principles.
WebLOAD 13.0 is now available for both SaaS and Self-hosted deployment, with identical functionality across both models, enabling customers to choose the right option for their unique needs.
Seems like RDVWF was impacted with Sep 28 policy!!
Any info on the next Quarterly financial report coming out. Last time they had a record profit!!
RDVWF Testing tool is No:1 as per QAInfotech!!
https://qainfotech.com/best-9-performance-testing-tools/
Seems like morning session cleared the 2+ million Sell block at 0.032. :):):)
if its broke the 0.032 resistance. it will go high fast!!
Very nice and a good one, most of the countries in Asia has the micro plastics in the ground water due to the poor waste management system. So definitely more and more nations in Asia will invite them, if the initial contracts are good.
Internet of Things (IoT) Performance Testing
With 10 billion connected devices today, the IoT market is expected to reach $520 billion in revenue in 2021. Over 86% of healthcare organizations utilize IoT technology, with similar trends noted in the electronics, travel, and aviation sectors. Due to the role IoT plays in these sectors, the performance of IoT apps is often critical. IoT performance and load testing validate the quality of the IoT application and its infrastructure by putting the entire ecosystem through a set of various dry-runs and simulations to identify issues. This article will dive into it and see how IoT Performance Testing differs from regular Performance and Load Testing. Let’s begin.
Although performance testing is never straightforward in any field, Internet of Things (IoT) testing poses additional challenges. Detecting a small error becomes much more complicated In the plethora of interconnected devices, and a single bug can affect the entire ecosystem. On top of that, these devices come with different operating systems, brands, native features, and data volumes.
Planning a series of load tests under these circumstances puts an extra burden on QA teams and IT staff while also presenting them with new challenges.
Full Arricle:
https://www.radview.com/blog/internet-of-things-performance-testing/?utm_campaign=IoT%20blog&utm_medium=Article&utm_source=Linkedin&utm_content=&utm_term=
??The secret sauce of eBay high #performance
eBay's team searched for a solution to run performance #benchmark testing on their #SAP Business Objects tool to overcome system performance fallbacks.
Using #WebLOAD they achieved:
?? #Racord and #Replay test scripts
?? Validate high performance within distributed #load
?? Achieve 52% performance gains
Learn More: https://bit.ly/3wVJwNE
#High #Velocity #Testing #Pipelin
Hope RadView's WebLoad tools will be able to grab a good share of Microsoft Customer in Market!!!
Load Testing Replacement for Microsoft’s Visual Studio and Azure DevOps
The world of Web Performance and Load testing is dynamic and changing all the time. New companies enter the world of testing, and others fade out. Performance and Load testing with Visual Studio Enterprise and Azure DevOps is one example of a load testing solution that is fading out.
While executing Web Performance and Load Tests via Visual Studio Enterprise and Azure DevOps (formerly known as VSTS) used to be a good option, Microsoft recently published that Visual Studio 2019 will be the last version of Visual Studio with load testing functionality. In addition to that, the cloud-based load testing service of Microsoft is also deprecated. This means that the Cloud load testing (CLT) functionality in Azure DevOps will soon be not available.
As a result, Microsoft urges customers to move to alternative load testing tools. In addition to that, in its documentation and product resources re Load Testing with Visual Studio Enterprise and Azure DevOps, Microsoft has been putting warnings to highlight these points similar to the one here and below re Visual Studio Enterprise load testing and below it and here re Azure DevOps cloud-based load testing.
“(!) Note: Web performance and load test functionality is deprecated. Visual Studio 2019 is the last version where web performance and load testing will be available. For more information, see the Cloud-based load testing service end of life blog post.” (emphasis added).
And similar to the warning below with regards to the Azure DevOps cloud based load testing (see here):
“(x) Caution: The cloud-based load testing service is deprecated. More information about the deprecation, the service availability, and alternative services can be found here. ” (emphasis added).
In this blog post we will review what this means to you, as a Visual Studio or Azure DevOps user, and what you can do moving forward with your existing load test project, in order to continue to load test your app or web application to ensure its optimal performance.
Edwin Hernandez, a Test Consultant at Microsoft, posted on Microsoft’s official blog, “What are the best Performance Testing Tools?” and included WebLOAD as one of the 5 best performance testing tools available today. In his blog he wrote:
“WebLoad is a full-featured enterprise-level load testing tool by RadView. It has many similar features compared to LoadRunner or Visual Studio Load Tests while it has a lower cost than LoadRunner… It is a pretty popular LoadRunner competitor and has been gaining market in the last years.” (emphasis added).
In fact, RadView’s WebLOAD is one of the world’s most advanced Load Testing platforms available on premise through its IDE / Recorder or in the Cloud / SaaS: It supports running Load Generators in the cloud on Azure similar to Azure DevOps and in addition with other cloud providers such as AWS, and Google Cloud . RadView also supports the following cloud based load testing deployment scenarios: SaaS / Cloud, Private Cloud, Hybrid and On Premise.
VSTS replacement
WebLOAD provides a single unified command and control interface where you can create load tests, execute, schedule, and analyze test results – all directly from your web browser.
The following table outlines how the concepts in Visual Studio load test, map to those in RadView’s WebLOAD. This together with RadView’s Enterprise Support and documentation, will enable you to easily migrate your load test and load test project to WebLOAD.
Mapping Table from Visual Studio Load Test to RadView’s WebLOAD
With the fading out of load testing tools as Performance and Load Testing with Visual Studio or Azure DevOps, choose WebLOAD as your replacement Load testing tool and assure the quality of your load tests, covered with the best support available in the industry. For more information, click here to get a comparison paper between WebLOAD and Visual Studio Load Test.
Contact RadView today to hear more about your replacement opportunities, or to get a live demo with one of our experts. In the demo we will discuss how you can migrate your web performance test and load test project to WebLOAD, how you can improve your web performance and load tests, and how you can easily create a web performance and load test, and analyze your load test results.
https://www.radview.com/blog/webload-the-best-replacement-for-microsofts-visual-studio-load-testing-capabilities/?utm_campaign=VSTS%20replacement&utm_medium=Article&utm_source=Linkedin&utm_content=&utm_term=
https://www.prweb.com/releases/sydor_technologies_the_laboratory_for_laser_energetics_look_to_redefine_ultrafast_in_diagnostic_light_detection/prweb18023371.htm
Sydor Technologies & the Laboratory for Laser Energetics Look to Redefine “Ultrafast” in Diagnostic Light Detection
Sydor Technologies has received a Small Business Innovation Research award in collaboration with Laboratory for Laser Energetics to explore the commercial viability of a tunable wavelength, ultrafast photodiode in support of ultrafast timing measurements required by fusion, high energy density and x-ray free electron laser facilities in the Department of Energy complex.
ROCHESTER, N.Y. (PRWEB) June 22, 2021
Sydor Technologies, a global provider of advanced x-ray detectors and diagnostic instrumentation for critical science missions and fundamental research, is pleased to announce that they have been awarded a $200,000 Small Business Innovation Research (SBIR) grant in collaboration with the Laboratory for Laser Energetics (LLE) at the University of Rochester. This grant will be used to investigate the commercial viability of a tunable wavelength, ultra-fast photodiode with a response time less than 50 picoseconds and high quantum efficiency in ultraviolet and x-ray wavelengths. No currently supported commercial photodiode matches these features. By experimenting with variations in semiconductor materials and employing novel electrode structures, the output of this ambitious collaboration will address the needs of fusion, high energy density physics (HED), and x-ray free electron laser facilities performing ultrafast timing measurements.
Sydor has a rich history of collaborating with scientists at leading universities to commercialize important advances in scientific diagnostic research, including the recent success of the Mixed Mode Pixel Array Detector (MM-PAD). This history combined with Sydor’s strengths in chemistry, physics, electronics, and aptitude for translating state-of-the-art technology into the delivery of commercially viable complex instruments are exactly what drives the collaboration with LLE. Dr. Valerie Fleischauer, Technology Development Scientist at Sydor Technologies, remarked, “The multidisciplinary engineering and scientific expertise at Sydor and the LLE will help to bring ultrafast photodiode technology out of the lab and in to the hands of scientists as a robust, easily deployable commercial device. I look forward to continuing the collaborative history with the LLE through this project that will provide unmatched ultrafast detection of ultraviolet and x-ray pulses to the HED community.”
Professor William Donaldson and his graduate students working at the LLE developed the technology required for the realization of these new detectors. By using new high-quality materials, the University of Rochester team produced a metal-semiconductor-metal photodiode fabricated on AlGaN devices that can resolve 25-ps ultraviolet pulses. Typically, ultraviolet photodiodes have response times nearly 100 times greater, limiting their applicability to high-bandwidth measurements. Bringing together the research team at LLE and Sydor Technologies through this SBIR will form the team that can bring this technology to the marketplace enabling critical measurements. Mike Campbell, Director at LLE said, “We are grateful to DOE for recognizing the promise of this technology and the quality of the team of Sydor, the University of Rochester, and LLE. LLE is committed to expanding our partnerships with local companies such as Sydor and helping to create high quality jobs with impactful technology to benefit our local economy."
About Sydor Technologies
Sydor Technologies is a global leader providing complex measurement solutions that generate critical results for the world’s most advanced applications in the defense, energy, ballistics, security, space, and research industries. Established in 2004 through technology originally transferred in collaboration with LLE, Sydor Technologies is headquartered in Rochester, NY and supplies systems and support in over 33 countries. For additional information, please visit http://www.SydorTechnologies.com.
About Laboratory for Laser Energetics
The LLE was established at the University in 1970 and is the largest US Department of Energy university-based research program in the nation primarily supported by the National Nuclear Security Administration as an integral part of its Stockpile Stewardship Program. Research at the LLE is also funded by the DOE’s Office of Science, the National Science Foundation, and New York State.
As a center for the investigation of the interaction of intense radiation with matter, the LLE is a unique national resource for research and education in science and technology. Current research includes exploring fusion as a future source of energy, developing new laser and materials technologies, and better understanding high-energy-density phenomena. In addition to its vital roles in various areas of scientific research and its support of the local high-tech economy, the LLE plays an important role in educating the next generation of scientists and engineers. For more information, please visit https://www.lle.rochester.edu.
The Best Load Testing Tool List: 3rd Best one from RAD view
Best load testing tools for automated performance testing are as follows:
Wapt
Apache JMeter
WebLOAD
Neotys Neoload
BlazeMeter
Load Impact
LoadFocus
Parasoft Load Test
Akamai CloudTest
TestPlant eggPlant Performance
https://techstorify.com/load-testing-tools/?utm_campaign=TechStorify%20best%20tools&utm_medium=Article&utm_source=Linkedin&utm_content=&utm_term=
Any one has the last Quarterly report financial statement link for Rad View
Alumifuel Power Signs Agreement with Ingenium Technologies
Huntsville, Ontario--(Newsfile Corp. - May 27, 2021) - Dinatrum/Alumifuel Power Corporation (OTC Pink: AFPW) ("Alumifuel" or the "Company") Mr. Pedro Villagran-Garcia, President & CEO, is pleased to announce that the company has signed an Agreement with Ingenium Technologies "Ingenium".
Ingenium Technologies provides a full range of component and system level design, analysis, development, integration, operations, software and technical writing expertise.
Ingenium Technologies has over 50 professionals with an average experience in excess of 25 years. Their careers cover commercial, military, space, undersea and land vehicles applications. Ingenium Technologies website link: https://bit.ly/3fjslOk
Ingenium was a Consultant in 2010 when Alumifuel gained control of a valuable and innovative Hydrogen Patent.
Alumifuel's CEO embarked in the task to complete an intensive search of all company Intangible Assets regarding its Hydrogen Applied Science and its R&D Investments. We promised results to our investors and shareholders.
As previously mentioned, and to be transparent and to provide in-depth information to our Shareholders, we would like to launch our new Alumifuel website https://www.alumifuelinc.com
Ingenium will assist Alumifuel in the upcoming commercial-scale production of the PBIS-1000 product. https://alumifuelinc.com/pbis-1000-prototype/
We will provide additional information on our plans since Alumifuel and Ingenium worked together on the Design and Production of this product.
For several years, the company invested in Hydrogen Technologies and Applied Sciences, therefore we consider ourselves an Industry Pioneer holding a name that directly associates with "Hydrogen" within the Alternative Fuel Investment Community.
As mentioned, we have filed a 10Q for the Third Quarter of 2016 and we are about to produce a filing for a 10K for 2016.
The company is continuing making an assessment on the companies that Control our Physical and Tangible Assets regarding Clean Energy, specifically related to Hydrogen. We recognize the importance of presenting Financial Statements and is working daily to present them to OTC Markets and to the Securities and Exchange Commission.
DINATRUM, INC./ALUMIFUEL POWER CORPORATION
Alumifuel Power Corporation commercializes unique Intellectual Property for high-demand Military and Commercial Applications, particularly focused on Hydrogen Technology. DINATRUM is a wholly owned subsidiary of Alumifuel Power Corporation and is a developer of Green Real Estate Projects in North America.
Our Social Media presence is displayed as follows:
Twitter: www.Twitter.com/afpw_ir
Facebook: www.facebook.com/dinatrum
Instagram: https://www.instagram.com/dinatrum13
LinkedIn: https://www.linkedin.com/company/dinatrum1
LinkedIn: https://www.linkedin.com/company/alumifuel
On behalf of the Board,
Pedro Villagran-Garcia,
President & CEO
Alumifuel Power Corporation
https://www.newsfilecorp.com/release/85523
Is there any dilution going on or dumping going on
OSE Immunotherapeutics Announces Dosing of the First Healthy Volunteer in Phase 1 Clinical Trial of its Multi-Variant Second-Generation COVID-19 Vaccine
May 26, 2021 01:30 ET | Source: OSE Immunotherapeutics
...
First-in-human study evaluating CoVepiT, a multi-variant T cell COVID-19 vaccine for people at risk and vulnerable populations.
CoVepiT is a peptide-based vaccine aiming to induce CD8+T-cell-mediated immune response against 11 different proteins of SARS-CoV-2 virus to provide a long-term cellular immunity with memory T cells.
Phase 1 study expected to read-out in September 2021.
NANTES, France, May 26, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) today announced that the first healthy volunteer has been enrolled and dosed in the Phase 1 clinical trial evaluating its COVID-19 vaccine, named CoVepiT.
This Phase 1 clinical trial is evaluating the safety, reactogenicity and immunogenicity of two dose regimen of CoVepiT in 48 healthy adult volunteers, previously vaccinated or not by an authorized COVID-19 vaccine (NCT04885361).
Alexis Peyroles, Chief Executive Officer of Immunotherapeutics, comments: “We are delighted with the progress achieved on the CoVepiT program to date with this first dosing being a significant milestone in our COVID-19 vaccine candidate’s development. We look forward to confirming our vaccine’s efficacy, providing people with broad and long-term protection against COVID-19 and its variants, particularly for more vulnerable population subgroups. The next phases of CoVepiT development are already under preparation, potentially expanding to other European countries while progressing with industrialization and manufacturing efforts. This further development is supported by a recent €10.7 million public funding from the French government via Bpifrance.”
The Phase 1 clinical trial of CoVepiT is based on the results from preclinical and human ex vivo studies demonstrating its potential to generate sentinel memory T cells with long-term protective effect against COVID-19. Targeting 11 virus proteins (including Spike, M, N and several non-structural proteins), this second-generation vaccine is designed to cover all initial and novel or upcoming SARS-CoV-2 variants.
ABOUT CoVepiT
CoVepiT is a next-generation multi-target, multi-variant vaccine against SARS-CoV-2 in clinical Phase 1. The vaccine candidate was designed using optimized epitopes selected after screening more than 67,000 global SARS-CoV-2 genomes, as well as those of previous human-infective CoVs, SARS and MERS, to identify vaccine targets with the lowest chance of natural mutation. Targeting 11 virus proteins including Spike, M, N and several non-structural proteins, this second-generation vaccine covers all initial and novel SARS-CoV-2 variants identified globally to date. In preclinical testing, CoVepiT demonstrated the ability to activate T cell defenses through CD8 T-cell multi-epitope responses for long-term T memory cell immunity.
ABOUT OSE Immunotherapeutics
OSE Immunotherapeutics is an integrated biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmune diseases. The company’s immunology research and development platform is focused on three areas: T-cell-based vaccination, Immuno-Oncology (focus on myeloid targets), Auto-immunity & Inflammation. Its balanced first-in-class clinical and preclinical portfolio has a diversified risk profile:
Vaccine platform
Tedopi® (innovative combination of neoepitopes): the company’s most advanced product; positive results for Step-1 of the Phase 3 trial (Atalante 1) in Non-Small Cell Lung Cancer post checkpoint inhibitor failure.
In Phase 2 in pancreatic cancer (TEDOPaM, sponsor GERCOR)
In Phase 2 in ovary cancer (TEDOVA, sponsor ARCAGY-GINECO)
Due to the COVID-19 crisis, accrual of new patients in TEDOPaM should restart in 2021.
CoVepiT: a prophylactic second-generation vaccine against COVID-19, developed using SARS-CoV-2 optimized epitopes against multi variants. Positive preclinical and human ex vivo results in August 2020. In clinical Phase 1.
Immuno-oncology platform
BI 765063 (OSE-172, anti-SIRPa mAb on SIRPa/CD47 pathway): developed in partnership with Boehringer Ingelheim in advanced solid tumors; positive Phase 1 results in monotherapy and BI 765063 dose escalation study ongoing in combination with Ezabenlimab (PD-1 antagonist).
CLEC-1 (novel myeloid checkpoint target): identification of mAb antagonists of CLEC-1 blocking the “Don’t Eat Me” signal that increase both tumor cell phagocytosis by macrophages and antigen capture by dendritic cells.
BiCKI®: bispecific fusion protein platform built on the key backbone component anti-PD-1 (OSE-279) combined with new immunotherapy targets; 2nd generation of PD-(L)1 inhibitors to increase antitumor efficacity.
Auto-immunity and inflammation platform
FR104 (anti-CD28 monoclonal antibody): Licensing partnership agreement with Veloxis in the organ transplantation market; ongoing Phase 1/2 in renal transplant (sponsored the Nantes University Hospital); Phase 2-ready asset in a niche indication in autoimmune diseases.
OSE-127/S95011 (humanized monoclonal antibody targeting IL-7 receptor): developed in partnership with Servier; positive Phase 1 results; in Phase 2 in ulcerative colitis (OSE sponsor) and an independent Phase 2a planned in Sjögren’s syndrome (Servier sponsor).
OSE-230 (ChemR23 agonist mAb): first-in-class therapeutic agent with the potential to resolve chronic inflammation by driving affected tissues to tissue integrity.
For more information:
Click and follow us on Twitter and LinkedIn
https://twitter.com/OSEIMMUNO
https://www.linkedin.com/company/10929673
Nothing to get Surprised!! if it happens in the Sub scents category stocks!! Ha!! Ha!!
High risk category includes every scenarios.
I hope the whole sub cents market runs in the same mechanism!!
With more exciting platform developments coming we have begun to prepare ARknet's availability for download in many more countries around the world significantly expanding our potential user base.
https://www.facebook.com/479462352536355/posts/1117495802066337/?d=n
The Path looks nice!! Testing Automation tool + Artificial Intelligence!!
The resistance is very thin for 0.01 cents!!
0.002 started showing up in the end!!
EQNX::TICKER_START (PinkSheets:HIPH),(Pinksheets:HIPH), EQNX::TICKER_END
The Company is poised to setup significant operations that will be an integral part of CaliBear launch in a market that is projected to be worth over $7 billion by 2025
via NewMediaWire -- American Premium Water Corporation (OTC: HIPH) (the "Company") announces it has come to terms on the acquisition of licenses to distribute and retail hemp cannabinoids in the State of New York as part of the State's program to establish quality control standards on the industry. The Company expects to close the transaction by the end of the 1st half 2021. (Disclosure: The Company acquired these licenses from a New York entity that was owned by CEO, Ryan Fishoff. The proposed consideration for the licenses is nominal.)
According to a report released by Grandview Research, New York State's cannabis market is expected to be worth over $7 billion by 2025. The New York State hemp cannabinoid program oversees the licensing of processors, distributors, and retailers, setting quality control standards that all hemp products must meet including manufacturing, packaging and labeling and laboratory testing requirements.
Ryan Fishoff, CEO of American Premium Water, commented, "I am excited to announce that the Company is set to acquire licenses to distribute and retail Hemp Cannabinoids in the State of New York. This is significant for the Company, as it further positions us to be dominant players in the Northeast. I feel that New York will become our hub for selling activities in the region. It is also my home state and I know from firsthand experience how under developed the CBD and Hemp market is in the city (and region); there is a huge opportunity to establish significant market share out of the gate. Getting these licenses allow us (The Company) to establish a foothold and further distinguish us from other companies trying to enter the space. The retail license could be utilized to partner with a non-CBD company to collaborate on retail installations and pop-up shops. There are a lot of empty storefronts in Manhattan and I believe there is great opportunity to capitalize off of this.
"Today is 4/20 and we are excited to celebrate it with this news. This announcement is a kickoff for the commercial launch of our joint venture with CaliBear. The Company is excited to begin selling CaliBear CBD products in the coming weeks. The Company will be doing a number of promotional activities and announcements in the coming weeks to prepare for the online and retail launches. Our distribution partner, Just Logistics, is excited to work with us on the initial rollout to smoke shops throughout the Northeast corridor. The Company is also engaged in discussions with other distributors along the east and west coasts to carry CaliBear CBD products. It's an exciting time and the CaliBear team of influencers have hit the beach, participating in Olympic qualifying tournaments in Cancun. We have also begun reaching out to non-CBD companies to explore partnership opportunities to expand the reach of the CaliBear brand, and increase sales. Having the Hemp Cannabinoid licenses will be an asset in these conversations and I look forward to getting creative with these partnerships to further distinguish the brand not only in the Hemp/CBD space, but become a market leader in the performance lifestyle segment. I encourage shareholders and investors to keep their eyes open for announcements in the coming weeks as preparations for the CaliBear retail launch heat up like the temperatures outside!" concluded Mr. Fishoff.
Shareholders and interested parties are encouraged to follow the Company's Twitter account @AmericanPremium and CEO Ryan Fishoff @RyanFishoff on Twitter for future Company updates, which will include material information about the Company. Parties are also encouraged to follow CaliBear influencer Taylor Crabb on Instagram at @KingCrabb808 as he competes in Olympic Qualifying tournaments in Cancun.
About American Premium Water Corp.
American Premium Water (OTC: HIPH) is a diversified luxury consumer products company focused on businesses in the health and beauty and biotech sectors. The company is focused on harnessing the powers of Nano technologies paired without cannabidiol (CBD) to treat health disorders and enhance quality of life. The company's portfolio includes the LALPINA Hydro and LALPINA CBD brands (www.lalpinahydrocbd.com), Cali Bear (www.calibear.life) Vanexxe (www.vanexxe.com) plant + body essentials (www.plantbodyessentials.co).
is there any news expected/Out?
ANN ARBOR, MI -- (April 19, 2021) – Minerco, Inc. “The Magic Mushroom Company” (OTC:MINE) today announced that American rapper and songwriter, Bobby Shmurda, has selected Minerco’s blockchain, a technology that enables cryptocurrencies such Minerco’s SHRUCOIN to bypass traditional sales channels, as the platform for fans to purchase tickets to his first concert after serving a six year prison sentence.
The concert, featuring Bobby Shmurda and Rowdy Rebel, will be released on June 19th as part of a docudrama to a combined global viewership of over 100 million subscribers through Amazon, Roku and Apple TV as well as its own channel, SHRUTV.com. The concert itself will be available exclusively to concertgoers who have purchased a ticket for $20 in SHURCOINS at www.shrucoin.com, which is owned and operated by Minerco, Inc. According to initial estimates, the Company believes a minimum of one million tickets will be sold primarily in North America, the Caribbean and Africa to this historic event, which is expected to result in record financial contributions to Minerco’s bottom-line both for the second fiscal quarter and current fiscal year ended December 31, 2021.
“Over the past several decades, the music industry has experienced significant devaluation,” said Julius Jenge, Chief Executive Officer of Minerco, Inc. “Technological advances that were created by companies based on a streaming subscription-based model adversely impacted both the artists and the industry as a whole. Ironically, it is innovative technologies, such as our SHRUCOIN, that is expected to drive a swift financial turnaround for the music industry as artists begin to see more and more appreciation for their work. We believe our blockchain technology will help decentralize the music business and instill a new generation of creativity and entrepreneurship to an industry that has been plagued by greed.”
He continued: “Our cryptocurrency platform solves an industry-wide problem and fills a huge void in the legal recreational and medical markets. Presently, commissary retail businesses are not allowed by financial institutions to accept payment for marijuana and other regulated products. They cannot accept credit & debit cards such as VISA or MasterCard. Now… customers can buy our SHRUCOIN with credit/debit cards from our site and then use our coins to complete their purchases. This can immediately be a game-changer for merchants in the industry.” To be added to the Company’s investor email lists, please email bmiller@irpartnersinc.com.
To learn more exciting info about Minerco, click here.
About Minerco, Inc. Minerco, Inc., "The Magic Mushroom Company" (OTC:MINE), is the pioneering company specializing in the research, production, and distribution of psilocybin mushroom products ("Magic Mushrooms"). The Blockchain token SHRU can be used for purchases relating to psilocybin and cannabis. SHRU can be purchased at www.shrucoin.com. Consumers can also utilize the SHRUCOIN Pay app by visiting www.shrucoinpay.com. To learn more about Minerco, Inc. please visit www.minercoinc.com.
GAMERICA Holdings and Acquisitions Corp. - VOIS, formerly Mind Solutions, Inc., is engaged in developing software applications, which are compatible with the Emotiv electroencephalography (EEG) headsets. The Company has developed and commercialized a Brain-Computer-Interface (BCI) called NeuroSync, which allows the user to operate thought-controlled applications on their mobile smart phone devices, as well as on personal computers. The BCI receives electrical impulses from the brain and allows the user to control actions on their smart phones and PCs through the power of thought. The technology involves the use of a wireless headset, which detects brainwaves on both the conscious and non-conscious level. The neural processing technology makes it possible for computers to interact directly with the human brain. The Company's products fall under two categories: software and hardware. The Company offers three thought-controlled software applications: Mind Mouse, Master Mind and Think-Tac-Toe.
Cool!!! - Total Sales and revenues for the three-month period that ended December 31, 2020 are up 52% compared to the same quarter last year, and more than doubled the total sales and revenues for the previous quarter.
/**************************************************************/
Radview Software Ltd-RDVWF), a leading provider of enterprise-grade performance and load testing solutions, today reported that the unaudited financial results for the three-month period ended Dec. 31, 2020 show increased momentum and record growth.
The report released today includes the growth summary as well as detailed description of the trend and growth factors that contributed to business acceleration during the fourth quarter, as well as the trend analysis vis-à-vis the previous quarters’ results.
Total Sales and revenues for the three-month period that ended December 31, 2020 are up 52% compared to the same quarter last year, and more than doubled the total sales and revenues for the previous quarter.
Despite the globally challenging economic conditions, the company recorded major achievements: Year-over-year growth for the same quarter and for the whole year is consistent and significant as it represents an over-achievement in terms of bookings across the board – new business, renewals, and upgrades – in both subscription and annual maintenance models.
In 2020 the Company has almost concluded the transition from a perpetual license business model to a subscription based (ARR) model.
“We are very pleased with our Q4 and whole year performance.” said Eyal Shalom, RadView’s CEO. “The results reinforce our conviction in our strategy and support our plans of expanding our product offering. We are optimistic about our ability to accelerate this growth in 2021.” concluded Shalom.
https://www.globenewswire.com/news-release/2021/03/15/2192969/0/en/Load-and-Performance-Testing-Leader-Radview-Announces-Fourth-Quarter-2020-Record-Growth.html
Testing in Production is a shift-right testing methodology that goes beyond the staging environment, which can never fully replicate the conditions in production. This is even more important when it comes to Load Testing. Click to learn more https://t.co/HkcEjevCfG pic.twitter.com/dscc68qTBM
— Radview Software (@RadViewSoftware) March 11, 2021